Skip to content Skip to footer
Subscribe Now
MAGAZINE

PharmaShots Magazine-June-2026 Edition

Shots: This edition explores Digital Vigilance: AI Enhancing Post-Market Safety Monitoring, highlighting how artificial intelligence, real-world data, and digital listening technologies are transforming pharmacovigilance into a proactive, predictive, and patient-centric discipline. Through expert perspectives, cover stories, and regulatory insights, we examine the opportunities and challenges of AI-driven safety surveillance—from social media signal detection and real-world…
11 hours ago

Read more

VIEWPOINTS

Jared Kelly on Immune Priming & Survival Outcomes: Oncolytics Biotech’s Vision for Pelareorep

Shots:  Oncolytics Biotech is advancing pelareorep beyond the traditional standalone therapy model, positioning the platform as a potential immune-priming backbone capable of enhancing immunotherapies, checkpoint inhibitors, chemotherapies, and other oncology treatments across multiple difficult-to-treat tumor settings.  The company continues generating growing survival and immune-engagement data across colorectal, pancreatic, and anal cancers, while emphasizing pelareorep’s potential to “turn cold tumors…
June 3, 2026

Read more

VIEWPOINTS

Advancing HES Care with AstraZeneca’s FASENRA: Insights from James Teague & Princess U. Ogbogu

Shots:  Could a targeted biologic therapy help address the longstanding unmet needs in hypereosinophilic syndrome (HES)? AstraZeneca’s FASENRA has now received US approval for HES, introducing a once-monthly treatment option for patients living with this rare and often underdiagnosed eosinophilic disorder  Results from the Phase III NATRON trial showed that FASENRA reduced the risk of first HES flare by 65% vs placebo,…
June 1, 2026

Read more

EVENTS

2026 HLTH Europe | June 15-18 | Amsterdam

HLTH Europe is the continent’s #1 healthcare innovation event. Following an enormously successful launch and the exponential growth of HLTH in the US, this landmark event is where global expertise meets local insight to address Europe’s unique healthcare challenges and opportunities. Unlock an exclusive €250 discount with PharmaShots! Use code HE26PHARMASHOTS at checkout to save…
May 14, 2026

Read more

VIEWPOINTS

Ending Prescription Ping-Pong in Specialty Care: Colin Banas, CMO, Timely By DrFirst Shares His Vision  

Shots:  Specialty medication access remains challenged by high costs, fragmented workflows, complex prior authorization requirements, and limited transparency, leading to delays, prescription drop-offs, and suboptimal patient outcomes.  DrFirst is addressing these gaps through AI-powered, workflow-integrated solutions that enable real-time benefits verification, targeted prior authorization automation, and smarter pharmacy routing, shifting care from reactive problem-solving to proactive, frictionless prescribing.  PharmaShots welcomes…
May 4, 2026

Read more

VIEWPOINTS

Jena Sophia on Breaking the Stress Code: Rewiring High Performance from Within 

Shots:  High performers often operate under a hidden layer of chronic stress, where sustained pressure subtly erodes decision-making, creativity, and emotional regulation, as subconscious patterns and past experiences continuously trigger a low-grade fight-or-flight response that impacts both performance and overall wellbeing  Lasting stress management requires going beyond surface-level techniques to address deep-rooted subconscious programming, where beliefs around identity, success,…
April 20, 2026

Read more

VIEWPOINTS

Innovation Meets Impact: Jaime Leija on BioLab’s Patient-First Approach

Shots:  BioLab balances innovation with real-world impact through a dual strategy that combines rapid commercialization of FDA-approved or near-market solutions like Imbed with continued investment in long-term innovations such as cureVision and terraplasma, ensuring both immediate clinical needs and future breakthroughs in wound care are effectively addressed.    BioLab’s growth is driven by sharp strategic discipline, focusing on chronic outpatient…
April 13, 2026

Read more

NEWS

DeepCyte Secures $1.5M to Advance AI-Driven Single-Cell Toxicology in Drug Development

Shots: DeepCyte, a techbio startup focused on advancing AI-powered toxicology for drug development, has officially launched with $1.5 million in seed funding, introducing two solutions to help biopharma teams detect, predict, and understand drug toxicity in human cells at single-cell resolution DeepCyte's MetaCore, a high-throughput single-cell metabolomics platform, leverages laser-based sampling and mass spectrometry to…
April 9, 2026

Read more

MAGAZINE

PharmaShots Magazine-April-2026 Edition

Shots: AI is redefining compliance from reactive to predictive, as this April edition highlights how AI-powered systems are transforming regulatory oversight into a continuous, real-time, and data-driven function, enabling early risk detection, automated audits, and smarter regulatory collaboration across the pharma value chain. Strategic dealmaking and AI partnerships shape industry momentum, with March witnessing high-value…
April 9, 2026

Read more

Load more